Ultragenyx Pharmaceutical Inc. (RARE) stock
RARENasdaqPharmaceutical PreparationsFiscal year ends December 31
$17.73+1.03 (+6.17%)
Close on Nov 18, 2026Market cap $1.75BP/E –Yield –
Ultragenyx Pharmaceutical cash
Cash and short-term investments held at the end of each period.
Ultragenyx Pharmaceutical's cash was $292.00M at Jun 30, 2026. For fiscal 2025 it was $680.00M, up 11.5% from the year before. Over ten years it grew 4.5% a year on average. The highest annual figure on record is $1.20B in fiscal 2020.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $680.00M | +11.5% |
| FY2024 | Dec 31, 2024 | $610.00M | +5.6% |
| FY2023 | Dec 31, 2023 | $577.63M | -22.8% |
| FY2022 | Dec 31, 2022 | $747.76M | +1.0% |
| FY2021 | Dec 31, 2021 | $740.20M | -38.4% |
| FY2020 | Dec 31, 2020 | $1.20B | +59.1% |
| FY2019 | Dec 31, 2019 | $755.23M | +64.3% |
| FY2018 | Dec 31, 2018 | $459.71M | +96.0% |
| FY2017 | Dec 31, 2017 | $234.49M | -38.3% |
| FY2016 | Dec 31, 2016 | $380.15M | -13.0% |
| FY2015 | Dec 31, 2015 | $437.00M | +133.1% |
| FY2014 | Dec 31, 2014 | $187.49M | +251.3% |
| FY2013 | Dec 31, 2013 | $53.38M | -38.1% |
| FY2012 | Dec 31, 2012 | $86.19M | +709.7% |
| FY2011 | Dec 31, 2011 | $10.65M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $292.00M | -40.1% |
| Q1 FY2026 | Mar 31, 2026 | $413.00M | -16.5% |
| Q4 FY2025 | Dec 31, 2025 | $680.00M | +11.5% |
| Q3 FY2025 | Sep 30, 2025 | $425.25M | -31.6% |
| Q2 FY2025 | Jun 30, 2025 | $487.28M | -36.2% |
| Q1 FY2025 | Mar 31, 2025 | $494.39M | +20.0% |
| Q4 FY2024 | Dec 31, 2024 | $610.00M | +5.6% |
| Q3 FY2024 | Sep 30, 2024 | $621.61M | +40.6% |
| Q2 FY2024 | Jun 30, 2024 | $763.82M | +38.4% |
| Q1 FY2024 | Mar 31, 2024 | $412.08M | -34.5% |
| Q4 FY2023 | Dec 31, 2023 | $577.63M | -22.8% |
| Q3 FY2023 | Sep 30, 2023 | $442.09M | -50.3% |
| Q2 FY2023 | Jun 30, 2023 | $551.98M | +1.7% |
| Q1 FY2023 | Mar 31, 2023 | $629.35M | +5.2% |
| Q4 FY2022 | Dec 31, 2022 | $747.76M | +1.0% |
| Q3 FY2022 | Sep 30, 2022 | $888.68M | +20.6% |
| Q2 FY2022 | Jun 30, 2022 | $542.80M | -35.8% |
| Q1 FY2022 | Mar 31, 2022 | $598.32M | -38.0% |
| Q4 FY2021 | Dec 31, 2021 | $740.20M | -38.4% |
| Q3 FY2021 | Sep 30, 2021 | $737.12M | -3.7% |
| Q2 FY2021 | Jun 30, 2021 | $845.76M | +4.0% |
| Q1 FY2021 | Mar 31, 2021 | $965.41M | +45.6% |
| Q4 FY2020 | Dec 31, 2020 | $1.20B | +59.1% |
| Q3 FY2020 | Sep 30, 2020 | $765.52M | +45.2% |
| Q2 FY2020 | Jun 30, 2020 | $813.42M | +31.6% |
| Q1 FY2020 | Mar 31, 2020 | $663.28M | -7.3% |
| Q4 FY2019 | Dec 31, 2019 | $755.23M | +64.3% |
| Q3 FY2019 | Sep 30, 2019 | $527.06M | +4.8% |
| Q2 FY2019 | Jun 30, 2019 | $618.29M | +13.0% |
| Q1 FY2019 | Mar 31, 2019 | $715.32M | +32.1% |
| Q4 FY2018 | Dec 31, 2018 | $459.71M | +96.0% |
| Q3 FY2018 | Sep 30, 2018 | $503.10M | +35.6% |
| Q2 FY2018 | Jun 30, 2018 | $547.13M | +36.9% |
| Q1 FY2018 | Mar 31, 2018 | $541.35M | +27.3% |
| Q4 FY2017 | Dec 31, 2017 | $234.49M | -38.3% |
| Q3 FY2017 | Sep 30, 2017 | $371.07M | -6.4% |
| Q2 FY2017 | Jun 30, 2017 | $399.65M | – |
| Q1 FY2017 | Mar 31, 2017 | $425.19M | – |
| Q4 FY2016 | Dec 31, 2016 | $380.15M | – |
| Q3 FY2016 | Sep 30, 2016 | $396.43M | – |
See a number that looks wrong?